ACADIA HEALTHCARE COMPANY INC

Company Overview

Acadia Healthcare Company Inc (ACHC) is a publicly traded behavioral healthcare provider focused on high‑acuity and complex mental health and substance use disorder treatment. At year‑end 2024 it operated 262 facilities (~11,850 beds) across 39 states and Puerto Rico, with services spanning acute inpatient psychiatry, detox/residential recovery, eating‑disorder programs and outpatient medication‑assisted treatment (163 comprehensive treatment centers). The business is highly scale‑and‑capability driven, generating $3.15 billion of revenue in 2024 with heavy government payor exposure (Medicaid ~56.5%, Medicare ~14.2%) and a growth strategy centered on bed expansions, de novo builds, joint ventures and acquisitions.

Executive Compensation Practices

Given Acadia’s asset‑heavy, expansion‑and‑M&A growth model, executive pay is likely tied to operational growth and capital metrics — e.g., same‑facility revenue, patient days/admissions, beds added, adjusted EBITDA, free cash flow and leverage reduction targets — rather than R&D milestones. Short‑term incentives will typically reward quarterly/annual revenue and margin performance (same‑facility revenue per patient day, occupancy), while long‑term incentives are likely equity‑based (stock awards, performance shares or RSUs) linked to multi‑year returns, integration success of acquisitions and covenant/compliance metrics given meaningful leverage (net leverage ~2.7x at 12/31/24; ~3.2x at Q2 2025). Because labor costs, regulatory outcomes, litigation expenses and reimbursement changes materially affect cash flow, compensation plans commonly include clawback, malus and compliance‑based gates and may incorporate specific quality, compliance and patient‑safety metrics to mitigate regulatory risk.

Insider Trading Considerations

Insider trading patterns at Acadia are likely to cluster around capital events (credit facility refinancings, senior note issuances, sizeable acquisitions), regulatory or litigation developments (e.g., government investigations, settlements like the Desert Hills matter), and material reimbursement or policy updates (Medicaid/OBBBA changes) that disproportionately affect revenue. Executives with equity awards may time sales when expansion milestones, improved same‑facility metrics, or repurchase authorizations are announced (company authorized a $300M repurchase program in 2025), but the presence of active investigations and potential material settlements increases the likelihood of trading restrictions, more frequent use of pre‑established Rule 10b5‑1 plans, and corporate blackout periods. Finally, because ~56–59% of revenue is Medicaid‑driven and interest rate/leverage exposure is meaningful, insiders should be monitored for trades near Medicaid policy announcements, covenant re‑pricing events, and other disclosures that materially shift cash‑flow or leverage outlook.